Immunome Inc. Files 8-K on Operations and Financials
Ticker: IMNM · Form: 8-K · Filed: May 14, 2024 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | May 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, filing
TL;DR
Immunome filed an 8-K updating its financial and operational status. Check it for details.
AI Summary
Immunome, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's principal executive offices located at 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011, and its telephone number is (610) 321-3700. This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This 8-K filing provides an update on Immunome Inc.'s operational and financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant new risks.
Key Players & Entities
- Immunome, Inc. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
- 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011 (address) — Address of principal executive offices
- (610) 321-3700 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Immunome, Inc.?
The primary purpose of this 8-K filing is to report on Immunome, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed or as of what date is it effective?
The report is dated May 14, 2024, and the date of the earliest event reported is also May 14, 2024.
What is the exact name and state of incorporation for the registrant?
The exact name of the registrant is Immunome, Inc., and it is incorporated in Delaware.
Where are Immunome, Inc.'s principal executive offices located?
Immunome, Inc.'s principal executive offices are located at 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011.
What is the registrant's telephone number, including area code?
The registrant's telephone number, including area code, is (610) 321-3700.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-05-14 08:02:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
Filing Documents
- tm2414252d1_8k.htm (8-K) — 26KB
- tm2414252d1_ex99-1.htm (EX-99.1) — 55KB
- 0001104659-24-060893.txt ( ) — 259KB
- immu-20240514.xsd (EX-101.SCH) — 3KB
- immu-20240514_lab.xml (EX-101.LAB) — 33KB
- immu-20240514_pre.xml (EX-101.PRE) — 22KB
- tm2414252d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On May 14, 2024, Immunome, Inc. (the "Company") announced its financial results for the first quarter ended March 31, 2024 and business update in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated May 14, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 14, 2024 Immunome, Inc. By: /s/ Max Rosett Name: Max Rosett Title: Chief Financial Officer